Skip to main content

Table 4 Comparison of clinical characteristics between patients with cyclosporine A-related neurotoxicity and those without

From: Cyclosporine A-related neurotoxicity after haploidentical hematopoietic stem cell transplantation in children with hematopathy

Characteristic Neurotoxicity Non-neurotoxicity P
No. of patients 7 44  
Male gender, n (%) 5 (72%) 34 (78%) 0.662
Age at HID-HSCT (years), median (range) 7 (1.6) 8 (4.4) 0.212
Underlying disease, n (%)    0.221
 Acute leukemia 6 (86%) 38 (87%)  
 Myelodysplastic syndrome 1 (14%) 1 (2%)  
 Aplastic anemia 0 (0%) 5 (11%)  
State of underlying disease at HSCT, n (%)    0.685
Complete remission 5 (72%) 25 (57%)  
Not in remission 2 (28%) 19 (43%)  
Hypertension after CSA, n (%) 5 (71%) 5 (11%) 0.002
Electrolyte imbalance, n (%)    
 Hyponatremia 3 (43%) 7 (16%) 0.095
 Hypokalemia 6 (86%) 33 (75%) 0.223
 Hypocalcemia 5 (71%) 18 (41%) 0.221
 Hypomagnesemia 2 (29%) 10 (23%) 0.662
Maximum trough CSA level > 250 ng/mL, n (%) 3 (43%) 12 (27%) 0.406
ABO blood type of donor and recipient, n (%)    0.427
 Matched 3 (43%) 27 (61%)  
 Mismatched 4 (57%) 17 (39%)  
Gender of donor and recipient, n (%)    0.923
 Matched 3 (43%) 18 (41%)  
 Mismatched 4 (57%) 26 (59%)  
Acute GvHD, n (%)    0.300
 Yes 5 (72%) 38 (86%)  
 No 2 (28%) 6 (14%)  
  1. CSA Cyclosporine A, HID-HSCT Haploidentical hematopoietic stem cell transplantation, SD Standard deviation, GvHD Graft-versus-host disease